Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQB: ATTBF) (CSE: ATT), is a specialty biotechnology company with capabilities through its wholly-owned subsidiaries as a botanical drug development company that develops and licenses natural health products, medicines, extractions and ingredients for the biologics, nutraceutical, bioceutical and cosmetic markets, some of which will contain cannabinoid compounds. Abattis develops and is in the process of commercializing natural health products that target ailments and satisfy important market needs. Abattis is conducting ongoing research and development to create plant-based intellectual property and ingredients. Current areas of focus are growth through acquisition and business development and cash flow through commercialization of existing assets.
Through our divisions Biocell Labs Inc. and Vergence Sales & Marketing Group, we develop and license natural health products and have future plans to expand into the nutraceutical, pharmaceutical and cosmetic markets. The Company has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding natural health product market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions.
Within our other divisions Northern Vine, North American Bioextracts and Biocube we have capabilities that support the production and extraction of botanical ingredients for our products; one of which includes cannabis.
Northern Vine LaboratoriesTM (Northern Vine LabsTM) seeks to become the premier analytical testing laboratory, and research and development partner to the legal cannabis industry in Canada - Executive Overview
For more information, visit the Company's website at: www.abattis.com.
Our investors are forward thinkers in the emerging bioceutical and medical marijuana markets. We are a specialty, vertically-integrated biotechnology company that aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. From patented and proprietary formulations, extraction and processing methods, Abattis consistently seeks opportunities to participate in varied markets all connected by a common global purpose and customer base: seeking health through natural products. Abattis is uniquely positioned to fully exploit the growing trend toward marijuana legalization in the United States and medicinal use in Canada as licensed and international jurisdictions.
“Health Canada estimates that the emerging medical marijuana market to be in excess of $1 billion.
Stephen Easton, an SFU Economist, estimated that nationally the Cannabis industry generates approximately $19 to $21 billion”
We develop and license natural health products with unique botanical blends, CBD and proprietary ingredients. These infused food and beverage brands are designed for wellness nutraceuticals, medical foods & botanical drugs market with future plans to expand into the pharmaceutical and cosmetic markets.
As an investor, you are our partner and we take this relationship seriously. Please contact us if you have any questions or if you would like to invest in Abattis.
Goldman Small Cap Research report, 'This Stock Set to Double Thanks to New License'
Abattis Bioceuticals Corp. - Stock Up Big on Recent News, Greater Gains on Horizon (October 20, 2016).
Goldman Small Cap Research report 'The Next Industry-Changing Specialty Health Stock'
Abattis Bioceuticals Corp. - Major Revenue Ahead for Innovative, Diversified Bioceuticals Pioneer (June 13, 2016).
Abattis Bioceuticals Corporation
Address: 104 - 9295 198th Street | Langley, BC V1M 3J9 | Canada
Phone: 778-883-7869 (Corporate Communications: Brook Bellian)
Email: [email protected]
Phone: (604) 336.0881
Phone: (604) 371.3371 | (604) 316.0982 | (604) 888.1129
CHINA | Dr. Shuang Xie Ph. D.
Suzhou Raybot Material Tech Ltd
T: 17785884380 | C: 17783175968
Phone: 86 5125240581 | 8613901388668
Address: No. 10-1 Yang Yuan Road,
Xinzhuang Zhen,Changshu | China
OUTSTANDING COMMON SHARE DATA
There are an unlimited number of common shares without par value authorized for issue. At September 30, 2016, there were 111,760,004 issued and fully paid common shares and 1,750,000 common shares in treasury.
Issued & Outstanding: The Company has 135,344,679 common shares issued and outstanding, 9,060,000 share purchase options outstanding and 17,101,425 share purchase warrants outstanding. On a fully diluted basis, 161,506,107, common shares were outstanding.
System for Electronic Document Analysis and Retrieval (SEDAR) - www.sedar.com If you want to add or to change something on this site - send a message to guay.